Speaker 9: All-new tonight, a controversial new treatment for depression. The FDA approved the antidepressant this week and it's a nasal spray. Speaker 10: Spravato is the first new type of ...

The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose: London Monday, March 24, 2025, 13:00 Hrs [IST] Hikma Pharmac ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of sufficient efficacy, the drug and medical device maker said on Thursday.

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Cisatracurium besylate injection has a market value of approximately $14 million in the 12 months ending January 2025, per ...

Weiner said the hope is this treatment could be used on a variety of traumatic brain injury patients, including football players with repetitive concussions. “We envision giving a nasal spray on ...

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE ...

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

The oxytocin system -- which helps release breast milk and strengthens the bond between mother and baby -- may be affected during breastfeeding in mothers experiencing postnatal depression.